Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN) announced that its CEO, Joshua Brumm, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 p.m. ET. This event will provide insights into Dyne's advancements in innovative therapeutics for muscle diseases. A live webcast can be accessed on their website, with a replay available for 30 days post-event. Dyne focuses on therapies for genetically driven diseases, leveraging its proprietary FORCE™ platform to tackle muscle tissue delivery challenges.

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present during the virtual 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of therapeutic candidates for serious muscle diseases, including myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

When is Dyne Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Dyne Therapeutics will present on January 12, 2022, at 2:15 p.m. ET.

Who will represent Dyne Therapeutics at the J.P. Morgan Healthcare Conference?

Joshua Brumm, the president and CEO, will represent Dyne Therapeutics.

How can I watch Dyne Therapeutics' presentation at the conference?

A live webcast of the presentation will be available on Dyne's Investors & Media section of their website.

What is the focus of Dyne Therapeutics?

Dyne Therapeutics focuses on developing innovative therapies for muscle diseases resulting from genetic disorders.

What platform does Dyne Therapeutics use for its therapeutic development?

Dyne Therapeutics utilizes its proprietary FORCE™ platform for developing oligonucleotide therapeutics.